natgillin/translations-raw huggingface dataset:
if you have experienced swelling, particularly of the face and throat, while taking other medicines (including angiotensin converting enzyme inhibitors).
če je v času jemanja drugih zdravil (kar vključuje tudi zaviralce angiotenzinske konvertaze) pri vas prišlo do otekanja, zlasti obraza in grla oziroma žrela.
How to take Amlodipine/Valsartan Mylan
Kako jemati zdravilo Amlodipin/valsartan Mylan
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Amlodipine/Valsartan Mylan 5 mg/160 mg.
Amlodipin/valsartan Mylan 10 mg/160 mg filmsko obložene tablete Zdravilo Amlodipin/valsartan Mylan 10 mg/160 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno nadzorovan samo z 10 mg amlodipina ali s 160 mg valsartana ali z jemanjem zdravila Amlodipin/valsartan Mylan 5 mg/160 mg.
The other ingredients are cellulose microcrystalline; crospovidone; magnesium stearate; silica colloidal anhydrous; hypromellose; macrogol 8000; talc; titanium dioxide (E171); iron oxide yellow (E172); iron oxide red (E172); iron oxide black (E172).
Pomožne snovi so: mikrokristalna celuloza, krospovidon, magnezijev stearat, brezvodni koloidni silicijev dioksid, hipromeloza, makrogol 8000, smukec, titanov dioksid (E171), rumeni železov oksid (E172), rdeči železov oksid (E172), črni železov oksid (E172).
In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene.
Po dajanju verapamila in intravenske infuzije dantrolena so pri živalih opazili ventrikularno fibrilacijo in srčno-žilni kolaps s smrtnim izidom, v povezavi s hiperkaliemijo.
The other ingredients are cellulose microcrystalline; crospovidone; magnesium stearate; silica colloidal anhydrous; hypromellose; macrogol 8000; talc, titanium dioxide (E171); iron oxide yellow (E172).
Pomožne snovi so: mikrokristalna celuloza, krospovidon, magnezijev stearat, brezvodni koloidni silicijev dioksid, hipromeloza, makrogol 8000, smukec, titanov dioksid (E171), rumeni železov oksid (E172).
The active substances of Amlodipine/Valsartan Mylan are amlodipine (as amlodipine besilate) and valsartan.
Kaj vsebuje zdravilo Amlodipin/valsartan Mylan Zdravilni učinkovini v zdravilu Amlodipin/valsartan Mylan sta amlodipin (v obliki amlodipinijevega besilata) in valsartan.
Common (may affect up to 1 in 10 people): Dizziness, sleepiness; palpitations (awareness of your heart beat); flushing, ankle swelling (oedema); abdominal pain, feeling sick (nausea).
Pogosti (pojavijo se pri največ 1 od 10 bolnikov): omotica, zaspanost; palpitacije (zavedanje bitja vašega srca); vročinski oblivi, otekanje gležnjev (edem); bolečine v trebuhu, slabost s siljenjem na bruhanje (navzea).
ACE inhibitors and angiotensin II receptor blockers (ARBs) should not be used concomitantly in patients with diabetic nephropathy.
Pri bolnikih z diabetično nefropatijo se zaviralcev ACE in antagonistov angiotenzinskih receptorjev II (ARB) ne sme uporabljati sočasno.
Uncommon Insomnia, mood changes (including anxiety), depression, tremor, dysgeusia, syncope, hypoesthesia, visual disturbance (including diplopia), tinnitus, hypotension, dyspnoea, rhinitis, vomiting, dyspepsia, alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, exanthema, myalgia, muscle cramps, pain, micturition disorder, increased urinary frequency, impotence, gynaecomastia, chest pain, malaise, weight increase, weight decrease.
Amlodipin pogosti somnolenca, omotica, palpitacije, bolečine v trebuhu, navzea, otekanje gležnjev nespečnost, spremembe razpoloženja (vključno z anksioznostjo), depresija, tremor, motnje v zaznavanju okusa, sinkopa, hipestezija, motnje vida (vključno z diplopijo), tinitus, hipotenzija, dispneja, rinitis, bruhanje, dispepsija, alopecija, purpura, obarvanje kože, hiperhidroza, srbenje, eksantem, mialgija, mišični krči, bolečine, motnje uriniranja, zvečana pogostnost uriniranja, impotenca, ginekomastija, bolečine v prsih, slabo počutje, zvečanje ali zmanjšanje telesne mase redki zmedenost zelo redki levkopenija, trombocitopenija, alergijske reakcije, hiperglikemija, hipertonija, periferna nevropatija, miokardni infarkt, aritmija (vključno z bradikardijo, ventrikularno tahikardijo in atrijsko fibrilacijo), vaskulitis, pankreatitis, gastritis, hiperplazija dlesni, hepatitis, zlatenica, zvišanje ravni jetrnih encimov*, angioedem, multiformni eritem, urtikarija, eksfoliativni dermatitis, Stevens-Johnsonov sindrom, Quinckejev edem, fotosenzitivnost
In an embryo-foetal development study in the rat, increased incidences of dilated ureters, malformed sternebrae, and unossified forepaw phalanges were noticed at exposures of about 12 (valsartan) and 10 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine.
V študiji embriofetalnega razvoja pri podganah so pri izpostavljenosti, ki je bila za valsartan okrog 12krat in za amlodipin okrog 10-krat večja kot ob kliničnih odmerkih 160 mg valsartana in 10 mg amlodipina, ugotovili večjo incidenco razširjenih ureterjev, malformirane sternebre in nezakostenele falange sprednjih tac.
Iron oxide yellow (E172) Iron oxide red (E172) Iron oxide black (E172)
Hipromeloza titanov dioksid (E171), makrogol 8000 smukec rumeni železov oksid (E172) rdeči železov oksid (E172) črni železov oksid (E172)
Uncommon (may affect up to 1 in 100 people): Dizziness; nausea and abdominal pain; dry mouth; drowsiness, tingling or numbness of the hands or feet; vertigo; fast heart beat including palpitations; dizziness on standing up; cough; diarrhoea; constipation; skin rash, redness of the skin; joint swelling, back pain; pain in joints.
Občasni (pojavijo se pri največ 1 od 100 bolnikov): omotica; slabost v želodcu in bolečine v trebuhu; suhost ust; zaspanost, mravljinčenje ali omrtvelost dlani in stopal; vrtoglavica; hitro bitje srca, vključno s palpitacijami; omotičnost stoje; kašelj; driska; zaprtje; osip, pordelost kože; oteklost sklepov, bolečine v hrbtu; bolečine v sklepih.
amlodipine/valsartan mylan 5 mg/160 mg
Amlodipin/valsartan Mylan 5 mg/160 mg
- If you get any side effects, talk to your doctor or pharmacist.
Če opazite katerikoli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure <90 mmHg at the end of the trial) in patients not adequately controlled on amlodipine 10 mg in 78 % of patients treated with amlodipine/valsartan 10 mg/160 mg, compared to 67 % of patients remaining on amlodipine 10 mg.
Pokazalo je, da se je krvni tlak normaliziral (najnižji diastolični krvni tlak sede < 90 mm Hg na koncu preskušanja) pri 78 % bolnikov, ki so dobivali amlodipin/valsartan 10 mg/160 mg, in pri 67 % bolnikov, ki so ostali na 10 mg amlodipina.
EU/1/16/1092/001 EU/1/16/1092/002 EU/1/16/1092/003 EU/1/16/1092/004 EU/1/16/1092/005 EU/1/16/1092/006 EU/1/16/1092/007 EU/1/16/1092/008 EU/1/16/1092/009 EU/1/16/1092/010 EU/1/16/1092/011 EU/1/16/1092/012 EU/1/16/1092/013 EU/1/16/1092/014 EU/1/16/1092/015 EU/1/16/1092/016 EU/1/16/1092/017 EU/1/16/1092/018 EU/1/16/1092/019 EU/1/16/1092/020 EU/1/16/1092/021 EU/1/16/1092/022 EU/1/16/1092/023 EU/1/16/1092/024 EU/1/16/1092/025 EU/1/16/1092/026 EU/1/16/1092/027 EU/1/16/1092/028 EU/1/16/1092/029 EU/1/16/1092/030 EU/1/16/1092/031 EU/1/16/1092/032 EU/1/16/1092/033 EU/1/16/1092/034 EU/1/16/1092/035 EU/1/16/1092/036 EU/1/16/1092/037 EU/1/16/1092/038 EU/1/16/1092/039
EU/1/16/1092/003 EU/1/16/1092/004 EU/1/16/1092/005 EU/1/16/1092/006 EU/1/16/1092/007 EU/1/16/1092/008 EU/1/16/1092/009 EU/1/16/1092/010 EU/1/16/1092/011 EU/1/16/1092/012 EU/1/16/1092/013 EU/1/16/1092/014 EU/1/16/1092/015 EU/1/16/1092/016 EU/1/16/1092/017 EU/1/16/1092/018 EU/1/16/1092/019 EU/1/16/1092/020 EU/1/16/1092/021 EU/1/16/1092/022 EU/1/16/1092/023 EU/1/16/1092/024 EU/1/16/1092/025 EU/1/16/1092/026 EU/1/16/1092/027 EU/1/16/1092/028 EU/1/16/1092/029 EU/1/16/1092/030 EU/1/16/1092/031 EU/1/16/1092/032 EU/1/16/1092/033 EU/1/16/1092/034 EU/1/16/1092/035 EU/1/16/1092/036 EU/1/16/1092/037 EU/1/16/1092/038 EU/1/16/1092/039
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone.
Amlodipin/valsartan Mylan 5 mg/160 mg filmsko obložene tablete Zdravilo Amlodipin/valsartan Mylan 5 mg/160 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno nadzorovan samo s 5 mg amlodipina ali s 160 mg valsartana.
Active-controlled trials in patients who were non-responders to monotherapy A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure <90 mmHg at the end of the trial) in patients not adequately controlled on valsartan 160 mg in 75 % of patients treated with amlodipine/valsartan 10 mg/160 mg and 62 % of patients treated with amlodipine/valsartan 5 mg/160 mg, compared to 53 % of patients remaining on valsartan 160 mg.
Pokazalo se je, da se je krvni tlak normaliziral (najnižji diastolični krvni tlak sede < 90 mm Hg na koncu preskušanja) pri 75 % bolnikov, ki so dobivali amlodipin/valsartan 10 mg/160 mg, pri 62 % bolnikov, ki so dobivali amlodipin/valsartan 5 mg/160 mg in pri 53 % bolnikov, ki so ostali na 160 mg valsartana.
Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and angiotensin II receptor blockers (ARBs).
Ti izsledki so pomembni tudi za druge zaviralce ACE in antagoniste angiotenzinskih receptorjev II (ARB), ker so njihove farmakodinamične lastnosti podobne.
The usual dose of Amlodipine/Valsartan Mylan is one tablet per day.
Običajni odmerek zdravila Amlodipin/valsartan Mylan je ena tableta na dan. Zaželeno je, da vzamete zdravilo vsak dan ob istem času.
• Concomitant use of Amlodipine/Valsartan Mylan with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and
• Sočasna uporaba zdravila Amlodipin/valsartan Mylan in zdravil, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (GFR
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets amlodipine/valsartan
Amlodipin/valsartan Mylan 5 mg/80 mg filmsko obložene tablete Amlodipin/valsartan Mylan 5 mg/160 mg filmsko obložene tablete Amlodipin/valsartan Mylan 10 mg/160 mg filmsko obložene tablete amlodipin/valsartan
CARTON FOR BOTTLE AND BLISTER BOTTLE LABEL
PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI ŠKATLA ZA PLASTENKO IN PRETISNI OMOT NALEPKA ZA PLASTENKO
What Amlodipine/Valsartan Mylan looks like and contents of the pack Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/80 mg tablets are light yellow, round, biconvex film-coated tablet marked with “AV1” on one side and “M” on the other side.
Izgled zdravila Amlodipin/valsartan Mylan in vsebina pakiranja Amlodipin/valsartan Mylan 5 mg/80 mg filmsko obložene tablete Tablete zdravila Amlodipin/valsartan 5 mg/80 mg so svetlo rumene, okrogle, bikonveksne filmsko obložene tablete z vtisnjeno oznako ''AV1'' na eni strani in ''M'' na drugi strani.
If ingestion is recent, induction of vomiting or gastric lavage may be considered.
Če je bolnik zdravilo zaužil pred kratkim, pride v poštev proženje bruhanja ali izpiranje želodca.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Light yellow, round, approximately 9 mm diameter, biconvex film-coated tablet debossed with “AV1” on one side and “M” on the other side.
Amlodipin/valsartan Mylan 5 mg/80 mg filmsko obložene tablete Svetlo rumene, okrogle, premera približno 9 mm, bikonveksne filmsko obložene tablete z vtisnjeno oznako ''AV1'' na eni strani in ''M'' na drugi strani.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets
Amlodipin/valsartan Mylan 5 mg/80 mg filmsko obložene tablete Amlodipin/valsartan Mylan 5 mg/160 mg filmsko obložene tablete Amlodipin/valsartan Mylan 10 mg/160 mg filmsko obložene tablete
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets amlodipine/valsartan
Amlodipin/valsartan Mylan 10 mg/160 mg filmsko obložene tablete amlodipin/valsartan
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg tablets are yellow, oval, biconvex film-coated tablet marked with “AV2” on one side and “M” on the other side.
Amlodipin/valsartan Mylan 5 mg/160 mg filmsko obložene tablete Tablete zdravila Amlodipin/valsartan 5 mg/160 mg so rumene, ovalne, bikonveksne filmsko obložene tablete z vtisnjeno oznako ''AV2'' na eni strani in ''M'' na drugi strani.
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, including valsartan.
Med sočasno uporabo litija in zaviralcev angiotenzinske konvertaze ali antagonistov angiotenzinskih receptorjev II, vključno z valsartanom, so poročali o reverzibilnem povečanju koncentracije litija v serumu in povečanju njegovih toksičnih učinkov.
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg tablets are light brown, oval, biconvex film-coated tablet marked with “AV3” on one side and “M” on the other side.
Amlodipin/valsartan Mylan 10 mg/160 mg filmsko obložene tablete Tablete zdravila Amlodipin/valsartan 10 mg/160 mg so svetlo rjave, ovalne, bikonveksne filmsko obložene tablete z vtisnjeno oznako ''AV3'' na eni strani in ''M'' na drugi strani.
Toxic Epidermal Necrolysis
Stenoza ledvične arterije
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Light brown, oval, approximately 15.6 mm × 7.8 mm, biconvex film-coated tablet debossed with “AV3” on one side and “M” on the other side.
Amlodipin/valsartan Mylan 10 mg/160 mg filmsko obložene tablete Svetlo rjave, ovalne, približno 15,6 x 7,8 mm velike, bikonveksne filmsko obložene tablete z vtisnjeno oznakko ''AV3'' na eni strani in ''M'' na drugi strani.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besilate) and 80 mg of valsartan.
Amlodipin/valsartan Mylan 5 mg/80 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 5 mg amlodipina (v obliki amlodipinijevega besilata) in 80 mg valsartana.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets amlodipine/valsartan
Amlodipin/valsartan Mylan 5 mg/80 mg filmsko obložene tablete amlodipin/valsartan
Sudden wheeziness, chest pain, shortness of breath or difficulty in breathing.
Psihiatrične motnje depresija anksioznost redki nespečnost/motnje spanja nihanje razpoloženja zmedenost redki
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets amlodipine/valsartan
Amlodipin/valsartan Mylan 5 mg/160 mg filmsko obložene tablete amlodipin/valsartan
Linearity Amlodipine and valsartan exhibit linear pharmacokinetics.
Linearnost Farmakokinetiki amlodipina in valsartana sta linearni.
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Yellow, oval, approximately 15.6 mm × 7.8 mm, biconvex film-coated tablet debossed with “AV2” on one side and “M” on the other side.
Amlodipin/valsartan Mylan 5 mg/160 mg filmsko obložene tablete Rumene, ovalne, približno 15,6 x 7,8 mm velike, bikonveksne filmsko obložene tablete z vtisnjeno oznako ''AV2'' na eni strani in ''M'' na drugi strani.
Amlodipine/valsartan should be discontinued immediately in patients who develop angioedema and should not be re-administered.
Bolnikom, pri katerih pride do angioedema, je treba amlodipin/valsartan takoj ukiniti.
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besilate) and 160 mg of valsartan.
Amlodipin/valsartan Mylan 10 mg/160 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 10 mg amlodipina (v obliki amlodipinijevega besilata) in 160 mg valsartana.
How to store Amlodipine/Valsartan Mylan
Shranjevanje zdravila Amlodipin/valsartan Mylan
Amlodipine/Valsartan Mylan is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Če želite dojiti, bo zdravnik za vas izbral drugo zdravilo, še posebno če je vaš otrok še novorojenček ali je bil rojen prezgodaj.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Each tablet contains 5 mg amlodipine and 80 mg valsartan.
Amlodipin/valsartan Mylan 5 mg/80 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 5 mg amlodipina in 80 mg valsartana.
Each tablet contains 10 mg amlodipine (as amlodipine besilate) and 160 mg valsartan.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 10 mg amlodipina (v obliki amlodipinijevega besilata) in 160 mg valsartana.
Each tablet contains 5 mg amlodipine (as amlodipine besilate) and 80 mg valsartan.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 5 mg amlodipina (v obliki amlodipinijevega besilata) in 80 mg valsartana.
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Each tablet contains 10 mg amlodipine and 160 mg valsartan.
Amlodipin/valsartan Mylan 10 mg/160 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 10 mg amlodipina in 160 mg valsartana.
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besilate) and 160 mg of valsartan.
Amlodipin/valsartan Mylan 5 mg/160 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 5 mg amlodipina (v obliki amlodipinijevega besilata) in 160 mg valsartana.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone.
Zdravilo Amlodipin/valsartan Mylan 5 mg/80 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno nadzorovan samo s 5 mg amlodipina ali z 80 mg valsartana.
Each tablet contains 5 mg amlodipine (as amlodipine besilate) and 160 mg valsartan.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 5 mg amlodipina (v obliki amlodipinijevega besilata) in 160 mg valsartana.
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Each tablet contains 5 mg amlodipine and 160 mg valsartan.
Amlodipin/valsartan Mylan 5 mg/160 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 5 mg amlodipina in 160 mg valsartana.
Oedema peripheral
Filmska obloga
Medicinal product subject to medical prescription.
Pogoji dovoljenja za promet z zdravilom
Heart failure/post-myocardial infarction
Motnje reprodukcije in dojk impotenca erektilna disfunkcija redki ginekomastija
Very rare Uncommon
zelo redki miokardni infarkt zelo redki
2 bottles with dosing syringe
2 Plastenki z merilno brizgo
8.4 g 7 pre-filled syringes
8.4 g 7 Napolnjene brizge
8.4 g 14 prefilled syringes
8.4 g 14 Napolnjene brizge
8.4 g 1 pre-filled syringe
8.4 g 1 Napolnjena brizga
This can happen especially if you are female or elderly.
To se lahko zgodi zlasti, če ste ženska ali starejša oseba.
Week 2 onwards: • Continue with the standard dose.
Teden 2 in naprej: • Nadaljujte z običajnim odmerkom.
2 to < 6 years
2 do < 6 let
In some patients additional factor VIII was given.
Nekaterim bolnikom so dajali dodaten faktor VIII.
For these reasons it is very important to inform your doctor of any change in your condition.
Zato je zelo pomembno, da obvestite svojega zdravnika o kakršni koli spremembi svojega stanja.
Such changes may in part be linked to disease control and lifestyle.
Take spremembe so lahko deloma povezane z nadzorom bolezni in življenjskim slogom.
Therefore, use in this population is not recommended.
Zato uporaba pri tej populaciji ni priporočljiva.
An interaction is possible.
Medsebojno delovanje je možno.
Interaction via effects on transport proteins cannot be excluded.
Medsebojnega delovanja zaradi učinkov na transportne proteine ne moremo izključiti.
• Swallow them whole with water.
• Pogoltnite cele z vodo.
Results of the “Low Age Group” are not shown as data are limited due to the small size of the group.
Rezultati za ''nizko starostno skupino'' niso prikazani, ker so podatki omejeni na majhno velikost skupine.
Do not take a double dose to make up for a forgotten individual dose.
Ne vzemite dvojnega odmerka, da bi nadomestili pozabljeni posamezni odmerek.
This is the approved combination regimen.
To je odobrena kombinacijska shema.
A causal relationship has been evoked, although the mechanism of action has not been elucidated.
Vzročno razmerje je bilo verjetno, čeprav mehanizem delovanja ni bil pojasnjen.
No long-term efficacy was evaluated with the modified regimen.
Dolgoročna učinkovitost s spremenjenim režimom ni bila ocenjena.
If indicated, prevention of further absorption can be considered.
Če je indicirano, razmislimo o preprečitvi nadaljnje absorpcije.
If you forget to take one dose, take this dose as soon as you remember together with some food.
Če pozabite vzeti en odmerek, ga zaužijte takoj, ko se spomnite, z nekaj hrane.
What Invirase is and what it is used for
Kaj je zdravilo Invirase in za kaj ga uporabljamo
INR (international normalised ratio) monitoring recommended.
Priporočljivo je spremljanje INR (mednarodno normalizirano razmerje).
Decreased appetite
občasni zmanjšanje apetita
Week 1:
Teden 1:
Your doctor will test for these changes.
Zdravnik bo glede teh sprememb opravil preiskave.
Standard Error
Standardna napaka
Absorption, distribution and elimination of each of the drugs are unchanged when they are used together.
Absorpcija, porazdelitev in izločanje vsakega od zdravil so pri sočasni uporabi nespremenjene.
This medicine should be taken during pregnancy only after consultation with your doctor.
To zdravilo se sme jemati med nosečnostjo samo po nasvetu vašega zdravnika.
Virological failure ITT/e*#
pomanjkanje virološkega odziva ITT/e*#
Combination not recommended.
Kombinacija se ne priporoča.
Any of these other medicines:
Katero koli izmed zdravil:
Continue to take this medicine until your doctor tells you otherwise.
Nadaljujte z jemanjem tega zdravila, dokler vam vaš zdravnik ne naroči drugače.
Lipid disorders should be managed as clinically appropriate.
Motnje lipidov je treba obravnavati, kot je klinično ustrezno.
• rifampicin - for preventing or treating tuberculosis
• rifampicin - za preprečevanje ali zdravljenje tuberkuloze,
Discuss with your physician the precautions needed to avoid infecting other people.
Posvetujte se z zdravnikom o previdnostnih ukrepih, potrebnih za preprečitev okužbe drugih ljudi.
In more than half of the reported cases, treatment with protease inhibitors was continued or reintroduced if treatment had been discontinued.
Pri več kot polovici poročanih primerov so z zdravljenjem z zaviralci proteaz nadaljevali ali ga ponovno uvedli, če je bilo zdravljenje prekinjeno.
No unexpected adverse events were observed in this study.
Nepričakovanih neželenih dogodkov v tej študiji niso opazili.
It is recommended that HIV-infected women do not breast feed their infants under any circumstances in order to avoid transmission of HIV.
Priporočljivo je, da s HIV okužene ženske svojih otrok v nobenih okoliščinah ne dojijo, da bi se izognili prenosu HIV.
The pharmacokinetic exposure parameters for the “High Age Group” are listed in Table 10.
Farmakokinetični parametri izpostavitve za ''visoko starostno skupino'' so navedeni v spodnji preglednici 10.
Four patients in the study experienced five adverse events that were considered related to trial treatment.
Štirje bolniki so v študiji izkusili pet neželenih dogodkov, za katere so smatrali, da so povezani s študijskim zdravljenjem.